Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

36.48 4.59

Overview

Share price change

24h

Current

Min

35.55

Max

36.88

Key metrics

By Trading Economics

Income

-5M

-128M

Sales

6.8M

11M

EPS

-1.23

Profit margin

-1,191.029

Employees

594

EBITDA

-5M

-127M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+142.23% upside

Dividends

By Acuity

Next Earnings

6 Aug 2026

Market Stats

By TradingEconomics

Market Cap

-619M

3.7B

Previous open

31.89

Previous close

36.48

News Sentiment

By Acuity

50%

50%

135 / 342 Healthcare

Crinetics Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

26 Jun 2026, 23:51 UTC

News

iShares 20+ Year Treasury Bond ETF declines in after-market trading amid heightened geopolitical tensions from military actions in the Middle East.

26 Jun 2026, 23:41 UTC

News

Charter Communications is in talks with SpaceX for a partnership to enhance mobile services using Starlink, with shares trading higher in after-market hours.

26 Jun 2026, 23:31 UTC

Social Media
News

Barclays raised its price target for Micron Technology, citing strong earnings and AI demand. Shares are higher in after-market trading alongside broader market gains.

26 Jun 2026, 23:26 UTC

Social Media
News
ETF Constituents

Invesco QQQ Trust gains in after-market trading as retail sentiment turns bullish, contrasting with declines in the broader market amid tech sell-off.

26 Jun 2026, 23:16 UTC

Social Media
News

Amazon's stock rises after AWS announces a notable price increase in Nvidia compute services. Wells Fargo maintains a Buy rating and sets a target of $312.

26 Jun 2026, 23:06 UTC

News

Amgen Inc shares declined in after-market trading following its revenue projections of $37.1 billion to $38.5 billion and significant debt of $57 billion.

26 Jun 2026, 23:02 UTC

News
ETF Constituents

SPDR Dow Jones Industrial Average ETF Trust rises in after-market trading, supported by gains from top holdings and the Dow's third consecutive weekly increase.

26 Jun 2026, 23:02 UTC

Social Media
ETF Constituents
News

SPDR S&P 500 ETF Trust rises in after-market trading following S&P's affirmation of U.S. sovereign ratings, reflecting positive economic growth expectations.

26 Jun 2026, 23:02 UTC

Social Media
News

The United States Oil Fund LP rose after military strikes in the Strait of Hormuz heightened concerns over oil supply stability and increased trading activity.

26 Jun 2026, 23:02 UTC

Social Media
News

Fox Corp shares are trading lower in after-market hours, despite strong preliminary viewership for the USA vs. Turkiye World Cup match and merger discussions.

26 Jun 2026, 23:01 UTC

News

Fox Corp shares are lower in after-market trading amid broader market concerns over inflation and weakening momentum in AI-driven stocks, despite strong viewership for FIFA matches.

26 Jun 2026, 20:15 UTC

News
Correlated Moves
ETF Constituents

Vanguard Large-Cap ETF trades lower in after-market hours, reflecting declines in major holdings and a drop in the S&P 500 Index.

26 Jun 2026, 20:07 UTC

Correlated Moves
News
Macro Event

Bitcoin is higher today, reflecting a slight gain since Thursday's close. The Goods Trade Balance widened to a record deficit of $105.8 billion.

26 Jun 2026, 20:07 UTC

Macro Event
News
Correlated Moves

Bitcoin is higher during Friday's session, reflecting a slight gain since Thursday. Broader market sentiment appears to influence both Bitcoin and Ethereum.

26 Jun 2026, 20:06 UTC

Correlated Moves
News

The US dollar's decline pressures USD/SGD, which has traded lower since Thursday. Broader inflation concerns are influencing the asset's performance today.

26 Jun 2026, 20:06 UTC

News

The USD/NOK is higher today, supported by recent currency market dynamics. The US dollar declines amid falling oil prices and weak technology shares.

26 Jun 2026, 20:05 UTC

Social Media
News

Tesla Inc. shares are higher, supported by a report showing 15.78% revenue growth and strong EBITDA of $2.43 billion, exceeding industry averages.

26 Jun 2026, 20:05 UTC

Social Media
News
Correlated Moves

Shares of Alphabet Inc. are trading lower amid concerns about Waymo's impact on competitors, as noted in a recent BTIG analysis.

26 Jun 2026, 20:05 UTC

Social Media
News

Microsoft shares are higher amid a market rally, fueled by Michael Burry's bullish sentiment and a valuation surpassing $2.75 trillion.

26 Jun 2026, 20:04 UTC

News

Bank of America Securities reiterated its Buy rating on Ulta Beauty, setting a price target of $685 after a meeting with company executives. Shares are higher today.

26 Jun 2026, 20:03 UTC

News
Correlated Moves
Social Media

Intel Corp shares are declining as the semiconductor sector faces pressure. High trading volume reflects increased investor activity amid mixed social media sentiment.

26 Jun 2026, 20:02 UTC

News
Correlated Moves
Social Media

Applied Materials Inc shares are lower amid a decline in the Semiconductor Materials & Equipment sector, despite recent price target increases from analysts.

26 Jun 2026, 19:56 UTC

News
Correlated Moves

The U.S. goods trade deficit widened to $105.8 billion in May 2026, influencing economic perceptions. Vanguard Total Bond Market ETF is higher since Thursday's close.

26 Jun 2026, 19:56 UTC

News
Correlated Moves

The U.S. goods trade deficit widened to $105.8 billion in May 2026, potentially impacting economic perceptions and Federal Reserve interest rate decisions.

26 Jun 2026, 19:52 UTC

Correlated Moves
News
Social Media

Broadcom Inc shares fell to $370.12, a 10-week low, amid a broader downturn in the semiconductor sector and negative investor sentiment.

26 Jun 2026, 19:52 UTC

Social Media
News

Qualcomm Inc's stock is lower amid concerns over competition and supply shortages following its new chip architecture announcements for smartphones and data centers.

26 Jun 2026, 19:52 UTC

Social Media
News
Correlated Moves

NVIDIA Corp shares are declining as Amazon Web Services raises GPU prices, potentially reducing demand. Market focus shifts to memory stocks amid broader pressures.

26 Jun 2026, 19:52 UTC

News

Costco Wholesale shares advanced following an insider sale of 885 shares for $847,345 and strong revenue growth of 11.58% over the past three months.

26 Jun 2026, 19:51 UTC

News

Biogen Inc pauses investment in most legacy Apellis programs, aligning with current objectives. Shares are higher today, reflecting positive investor response to the restructuring.

26 Jun 2026, 19:46 UTC

News
Correlated Moves
Social Media

Meta Platforms is advancing as it accelerates its shift to generative AI for content moderation, despite concerns about compliance and valuation compared to peers.

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

142.23% upside

12 Months Forecast

Average 88.9 USD  142.23%

High 97 USD

Low 80 USD

Based on 11 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

11

Buy

0

Hold

0

Sell

Sentiment

By Acuity

135 / 342 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat